FrancophonIA/ELRC3.0 huggingface dataset:
English: 14 hard capsules: EU/1/09/525/001 28 hard capsules: EU/1/09/525/002 30 hard capsules: EU/1/09/525/003 56 hard capsules: EU/1/09/525/004 60 hard capsules: EU/1/09/525/005 112 hard capsules: EU/1/09/525/006 200 hard capsules: EU/1/09/525/047 250 hard capsules: EU/1/09/525/007
Estonian: 14 kõvakapslit: EU/1/09/525/001 28 kõvakapslit: EU/1/09/525/002 30 kõvakapslit: EU/1/09/525/003 56 kõvakapslit: EU/1/09/525/004 60 kõvakapslit: EU/1/09/525/005 112 kõvakapslit: EU/1/09/525/006 200 kõvakapslit: EU/1/09/525/047 250 kõvakapslit: EU/1/09/525/007
English: • Trembling
Estonian: Treemor
English: Excipient with known effect: Each orodispersible tablet contains 10.5 µg sorbitol E420.
Estonian: Teadaolevat toimet omavad abiained: Üks suus dispergeeruv tablett sisaldab 10,5 µg sorbitooli (E420).
English: Insomnia Anxiety Restlessness
Estonian: Luupainajad Agitatsioon Segasus
English: 112 hard capsules: EU/1/09/525/018 200 hard capsules: EU/1/09/525/049 250 hard capsules: EU/1/09/525/019
Estonian: 112 kõvakapslit: EU/1/09/525/018 200 kõvakapslit: EU/1/09/525/049 250 kõvakapslit: EU/1/09/525/019
English: - The other ingredients for Nimvastid 3 mg, 4.5 mg and 6 mg capsules are microcrystalline cellulose, hypromellose, colloidal anhydrous silica, magnesium stearate in the capsule content,
Estonian: - Teised abiained Nimvastid 3 mg, 4,5 mg ja 6 mg kapslitel on mikrokristalliline tselluloos, hüpromelloos, veevaba kolloidne ränidioksiid, magneesiumstearaat kapsli sisus ja titaandioksiid (E171), kollane raudoksiid (E172), punane raudoksiid (E172) ja želatiin kapsli kestas.
English: 28 hard capsules: EU/1/09/525/008
Estonian: 28 kõvakapslit: EU/1/09/525/008
English: You may have side effects more often when you start your medicine or when your dose is increased.
Estonian: Kõrvaltoimete esinemissagedus võib olla kõrgem ravi alustamisel või annuse suurendamise järgselt.
English: - if you have, or have ever had, seizures.
Estonian: - kui teil on või on kunagi olnud maksatalitluse langus.
English: Nimvastid 4.5 mg orodispersible tablets
Estonian: Nimvastid 4,5 mg suus dispergeeruvad tabletid
English: Excipient with known effect: Each orodispersible tablet contains 5.25 µg sorbitol E420.
Estonian: Teadaolevat toimet omavad abiained: Üks suus dispergeeruv tablett sisaldab 5,25 µg sorbitooli (E420).
English: Hydroxypropylcellulose
Estonian: Mikrokristalne tselluloos Hüpromelloos
English: 112 hard capsules: EU/1/09/525/012 200 hard capsules: EU/1/09/525/048 250 hard capsules: EU/1/09/525/013
Estonian: 112 kõvakapslit: EU/1/09/525/012 200 kõvakapslit: EU/1/09/525/048 250 kõvakapslit: EU/1/09/525/013
English: 30 hard capsules: EU/1/09/525/009
Estonian: 30 kõvakapslit: EU/1/09/525/009
English: Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Estonian: Idiopaatilise Parkinsoni tõvega kaasneva kerge kuni keskmise raskusega dementsuse sümptomaatiline ravi.
English: 112 hard capsules: EU/1/09/525/024 200 hard capsules: EU/1/09/525/050 250 hard capsules: EU/1/09/525/025
Estonian: 112 kõvakapslit: EU/1/09/525/024 200 kõvakapslit: EU/1/09/525/050 250 kõvakapslit: EU/1/09/525/025
English: 60 hard capsules: EU/1/09/525/017
Estonian: 60 kõvakapslit: EU/1/09/525/017
English: Very common (may affect more than 1 in 10 people)
Estonian: Väga sage (võib esineda rohkem kui 1 inimesel 10-st) - värinad - minestamine - juhuslik kukkumine
English: Each orodispersible tablet contains rivastigmine hydrogen tartrate equivalent to 1.5 mg rivastigmine.
Estonian: Üks suus dispergeeruv tablett sisaldab rivastigmiinvesiniktartraati koguses, mis vastab 1,5 mg rivastigmiinile.
English: Rivastigmine
Estonian: Annustamine
English: • Heartburn
Estonian: Pearinglus
English: Nimvastid 4.5 mg hard capsules, which contain a white to almost white powder, have a brownish red cap and brownish red body.
Estonian: Nimvastid 4,5 mg kõvakapslitel, mis sisaldavad valget kuni peaaegu valget värvi pulbrit, on pruunikaspunane kaas ja pruunikaspunane keha.
English: Nimvastid 6 mg orodispersible tablets
Estonian: Nimvastid 6 mg suus dispergeeruvad tabletid
English: • Feeling agitated
Estonian: Häiritud liigutused
English: 28 hard capsules: EU/1/09/525/014
Estonian: 28 kõvakapslit: EU/1/09/525/014
English: - The active substance is rivastigmine hydrogen tartrate.
Estonian: Mida Nimvastid sisaldab - Toimeaine on rivastigmiinvesiniktartraat.
English: 60 hard capsules: EU/1/09/525/023
Estonian: 60 kõvakapslit: EU/1/09/525/023
English: • Decreased appetite
Estonian: Vähenenud söögiisu Vedelikukaotus
English: Nimvastid 3 mg orodispersible tablets
Estonian: Nimvastid 3 mg suus dispergeeruvad tabletid
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING
Estonian: Lisainfot vt pakendi infolehest.
English: Each hard capsule contains rivastigmine hydrogen tartrate equivalent to 1.5 mg rivastigmine.
Estonian: Üks kõvakapsel sisaldab rivastigmiinvesiniktartraati koguses, mis vastab 1,5 mg rivastigmiinile.
English: 56 hard capsules: EU/1/09/525/016
Estonian: 56 kõvakapslit: EU/1/09/525/016
English: • Feeling dizzy
Estonian: Rebi Eemalda
English: 30 hard capsules: EU/1/09/525/021
Estonian: 30 kõvakapslit: EU/1/09/525/021
English: 28 hard capsules: EU/1/09/525/020
Estonian: 28 kõvakapslit: EU/1/09/525/020
English: Tear.
Estonian: Suukaudne.
English: White to almost white powder in a capsule with a brownish red cap and orange body.
Estonian: Valget kuni peaaegu valget värvi pulber pruunikaspunase kaane ja oranži kehaga kapslis.
English: 56 hard capsules: EU/1/09/525/010
Estonian: 56 kõvakapslit: EU/1/09/525/010
English: 56 hard capsules: EU/1/09/525/022
Estonian: 56 kõvakapslit: EU/1/09/525/022
English: 30 hard capsules: EU/1/09/525/015
Estonian: 30 kõvakapslit: EU/1/09/525/015
English: Capsule content Microcrystalline cellulose Hypromellose Silica, colloidal anhydrous Magnesium stearate
Estonian: Mikrokristalne tselluloos Hüdroksüpropüültselluloos
English: Each orodispersible tablet contains rivastigmine hydrogen tartrate equivalent to 4.5 mg rivastigmine.
Estonian: Üks suus dispergeeruv tablett sisaldab rivastigmiinvesiniktartraati koguses, mis vastab 4,5 mg rivastigmiinile.
English: 60 hard capsules: EU/1/09/525/011
Estonian: 60 kõvakapslit: EU/1/09/525/011
English: Nimvastid 3 mg hard capsules
Estonian: Nimvastid 3 mg kõvakapslid
English: • Depression
Estonian: Depressioon Agressioon
English: Each hard capsule contains rivastigmine hydrogen tartrate equivalent to 4.5 mg rivastigmine.
Estonian: Üks kõvakapsel sisaldab rivastigmiinvesiniktartraati koguses, mis vastab 4,5 mg rivastigmiinile.
English: Nimvastid 4.5 mg hard capsules
Estonian: Nimvastid 4,5 mg kõvakapslid
English: Nimvastid 6 mg hard capsules
Estonian: Nimvastid 6 mg kõvakapslid
English: Each hard capsule contains rivastigmine hydrogen tartrate equivalent to 6 mg rivastigmine.
Estonian: Üks kõvakapsel sisaldab rivastigmiinvesiniktartraati koguses, mis vastab 6 mg rivastigmiinile.
English: Nimvastid 1.5 mg hard capsules
Estonian: Nimvastid 1,5 mg kõvakapslid
English: Each orodispersible tablet contains rivastigmine hydrogen tartrate equivalent to 6 mg rivastigmine.
Estonian: Üks suus dispergeeruv tablett sisaldab rivastigmiinvesiniktartraati koguses, mis vastab 6 mg rivastigmiinile.
English: 14 x 1 orodispersible tablet:EU/1/09/525/026 28 x 1 orodispersible tablet:EU/1/09/525/027 30 x 1 orodispersible tablet:EU/1/09/525/028 56 x 1 orodispersible tablet:EU/1/09/525/029 60 x 1 orodispersible tablet:EU/1/09/525/030 112 x 1 orodispersible tablet:EU/1/09/525/031
Estonian: 14 x 1 suus dispergeeruv tablett: EU/1/09/525/026 28 x 1 suus dispergeeruv tablett: EU/1/09/525/027 30 x 1 suus dispergeeruv tablett: EU/1/09/525/028 56 x 1 suus dispergeeruv tablett: EU/1/09/525/029 60 x 1 suus dispergeeruv tablett: EU/1/09/525/030 112 x 1 suus dispergeeruv tablett: EU/1/09/525/031
English: Each hard capsule contains rivastigmine hydrogen tartrate equivalent to 3 mg rivastigmine.
Estonian: Üks kapsel sisaldab rivastigmiinvesiniktartraati koguses, mis vastab 3 mg rivastigmiinile (Rivastigminum).
English: Each orodispersible tablet contains rivastigmine hydrogen tartrate equivalent to 3 mg rivastigmine.
Estonian: Üks suus dispergeeruv tablett sisaldab rivastigmiinvesiniktartraati koguses, mis vastab 3 mg rivastigmiinile.
English: • Stomach problems such as feeling sick (nausea) or being sick (vomiting), diarrhoea
Estonian: Väga sage (võib esineda rohkem kui 1 inimesel 10-st) - pearinglus - isutus - maohäired - halb enesetunne (iiveldus) või haigus (oksendamine), kõhulahtisus
English: No untoward effects on cardiac conduction were observed following concomitant administration of digoxin and rivastigmine.
Estonian: Digoksiini ja rivastigmiini koos manustamisel ei täheldatud kahjustavat toimet südame juhtesüsteemi.
English: 28 x 1 orodispersible tablet:EU/1/09/525/042 30 x 1 orodispersible tablet:EU/1/09/525/043 56 x 1 orodispersible tablet:EU/1/09/525/044 60 x 1 orodispersible tablet:EU/1/09/525/045 112 x 1 orodispersible tablet:EU/1/09/525/046
Estonian: 28 x 1 suus dispergeeruv tablett: EU/1/09/525/042 30 x 1 suus dispergeeruv tablett: EU/1/09/525/043 56 x 1 suus dispergeeruv tablett: EU/1/09/525/044 60 x 1 suus dispergeeruv tablett: EU/1/09/525/045 112 x 1 suus dispergeeruv tablett: EU/1/09/525/046
English: 28 x 1 orodispersible tablet:EU/1/09/525/037 30 x 1 orodispersible tablet:EU/1/09/525/038 56 x 1 orodispersible tablet:EU/1/09/525/039 60 x 1 orodispersible tablet:EU/1/09/525/040 112 x 1 orodispersible tablet:EU/1/09/525/041
Estonian: 28 x 1 suus dispergeeruv tablett: EU/1/09/525/037 30 x 1 suus dispergeeruv tablett: EU/1/09/525/038 56 x 1 suus dispergeeruv tablett: EU/1/09/525/039 60 x 1 suus dispergeeruv tablett: EU/1/09/525/040 112 x 1 suus dispergeeruv tablett: EU/1/09/525/041
English: They may respond to a dose reduction.
Estonian: Tekkinud kõrvaltoimed võivad taanduda pärast annuse vähendamist.
English: 28 x 1 orodispersible tablet:EU/1/09/525/032 30 x 1 orodispersible tablet:EU/1/09/525/033 56 x 1 orodispersible tablet:EU/1/09/525/034 60 x 1 orodispersible tablet:EU/1/09/525/035 112 x 1 orodispersible tablet:EU/1/09/525/036
Estonian: 28 x 1 suus dispergeeruv tablett: EU/1/09/525/032 30 x 1 suus dispergeeruv tablett: EU/1/09/525/033 56 x 1 suus dispergeeruv tablett: EU/1/09/525/034 60 x 1 suus dispergeeruv tablett: EU/1/09/525/035 112 x 1 suus dispergeeruv tablett: EU/1/09/525/036
English: • Ulcers in your stomach or intestine
Estonian: Kõhuvalu ja düspepsia
English: • Uneven heartbeat
Estonian: Südame häired Sage
English: Gastrointestinal disorders Very common Very common Very common Common
Estonian: Seedetrakti häired Väga sage Väga sage Väga sage Sage
English: - if you have, or have ever had, an active stomach ulcer.
Estonian: - kui teil on või on kunagi olnud äge maohaavand.
English: White to almost white powder in a capsule with brownish red cap and brownish red body.
Estonian: Valget kuni peaaegu valget värvi pulber pruunikaspunase kaane ja pruunikaspunase kehaga kapslis.
English: Nightmares
Estonian: Neerukahjustus
English: Breast-feeding
Estonian: Bradükineesia
English: Check with your doctor, pharmacist or nurse if you are not sure.
Estonian: Kui te ei ole milleski kindel, pidage nõu oma arsti, apteekri või meditsiiniõega.
English: Talk to your doctor before taking Nimvastid: - if you have, or have ever had, irregular or slow heartbeat.
Estonian: - kui teil esinevad või on kunagi esinenud südame rütmihäired või aeglane südame löögisagedus.
English: It is used in the following groups:
Estonian: Seda kasutatakse järgmistel patsiendirühmadel:
English: The full EPAR and risk management plan summary for Eptifibatide Accord can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Eptifibatide Accordi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The recommended dose is 180 micrograms per kilogram body weight given as an injection into a vein as soon as possible after diagnosis.
Estonian: Soovitatav annus on 180 mikrogrammi kilogrammi kehamassi kohta manustatuna süstina veeni niipea kui võimalik pärast diagnoosimist.
English: A risk management plan has been developed to ensure that Eptifibatide Accord is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Eptifibatide Accordi võimalikult ohutu kasutamine.
English: The company provided data from the published literature on eptifibatide.
Estonian: Ettevõte esitas eptifibatiidi kohta avaldatud kirjandusest pärinevad andmed.
English: What measures are being taken to ensure the safe and effective use of Eptifibatide Accord?
Estonian: Mis meetmed võetakse, et tagada Eptifibatide Accordi ohutu ja efektiivne kasutamine?
English: This is followed by a continuous infusion of 2.0 microgram/kg per minute which is continued for up to 72 hours, until the start of heart surgery, or until discharge from the hospital, whichever occurs first.
Estonian: Sellele järgneb 2,0 µg/kg/min pidevinfusioon kestusega kuni 72 tundi kuni südameoperatsiooni alguseni või haiglast väljakirjutamiseni (olenevalt sellest, kumb toimub varem).
English: The Committee recommended that Eptifibatide Accord be approved for use in the EU.
Estonian: Komitee soovitas Eptifibatide Accordi kasutamise Euroopa Liidus heaks kiita.
English: This sticking together of platelets is an important step in forming a blood clot, and when it happens in the blood vessels supplying the heart it can lead to a heart attack.
Estonian: Trombotsüütide agregatsioon on oluline etapp verehüübe moodustumisel ja kui see toimub südant verega varustavas veresoones, võib see põhjustada südameinfarkti.
English: The active substance in Eptifibatide Accord, eptifibatide, stops the platelets aggregating by blocking a protein called glycoprotein IIb/III on their surface that helps make them sticky.
Estonian: Eptifibatide Accordi toimeaine eptifibatiid peatab trombotsüütide agregatsiooni, blokeerides nende pinnal valgu glükoproteiin IIb/IIIa, mis muudab need kleepuvaks.
English: This reduces the risk of a blood clot forming and helps prevent heart attacks.
Estonian: See vähendab verehüüvete tekkimist ja aitab ennetada südameinfarkte.
English: Eptifibatide Accord is a medicine used to prevent a heart attack in adults.
Estonian: Eptifibatide Accord on ravim, mida kasutatakse südameinfarkti ennetamiseks täiskasvanutel.
English: No additional studies were needed as Eptifibatide Accord is a generic medicine that is given by injection and infusion into a vein and contains the same active substance as the reference medicine, Integrilin.
Estonian: Lisauuringuid ei olnud vaja, sest Eptifibatide Accord on süsti ja infusioonina manustatav geneeriline ravim, mis sisaldab sama toimeainet kui võrdlusravim Integrilin.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Eptifibatide Accord has been shown to be comparable to Integrilin.
Estonian: Inimravimite komitee järeldas, et Euroopa Liidu nõuete kohaselt on tõendatud ravimi Eptifibatide Accord sarnane toime ravimiga Integrilin.
English: Eptifibatide Accord is given with aspirin and unfractionated heparin (other medicines that prevent blood clots).
Estonian: Eptifibatide Accordi manustatakse koos aspiriini ja fraktsioneerimata hepariiniga (vere hüübimist pärssivad ravimid).
English: • patients who have unstable angina (chest pain caused by poor blood flow to the heart, that may occur at rest or without an obvious trigger);
Estonian: • patsiendid, kellel on ebastabiilne stenokardia (rinnavalu, mida põhjustab südame halb verevarustus, mis võib toimuda puhkeolekus või ilma nähtava vallandajata);
English: Eptifibatide Accord eptifibatide
Estonian: Eptifibatide Accord eptifibatiid
English: Patients who have moderately reduced kidney function should receive a lower dose during the infusion.
Estonian: Mõõdukalt halvenenud neerutalitlusega patsiendid peavad infusiooni ajal saama väiksema annuse.
English: The medicine contains the active substance eptifibatide.
Estonian: Ravim sisaldab toimeainena eptifibatiidi.
English: Because Eptifibatide Accord is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Eptifibatide Accord on geneeriline ravim, peetakse tema kasulikkust ja riske samaks mis võrdlusravimil.
English: Therefore, the CHMP's view was that, as for Integrilin, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka Integrilini korral, ületab ravimi kasulikkus sellega kaasnevad riskid.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Eptifibatide Accord, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Eptifibatide Accordi omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: This means that Eptifibatide Accord is similar to a ‘reference medicine' already authorised in the European Union (EU) called Integrilin.
Estonian: See tähendab, et Eptifibatide Accord on sarnane võrdlusravimiga Integrilin, millel juba on Euroopa Liidus müügiluba.
English: For practical information about using Eptifibatide Accord, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Eptifibatide Accordi kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: • patients who have already had a non-Q-wave myocardial infarction (a type of heart attack), with chest pain in the last 24 hours and with abnormalities on the electrocardiogram (ECG) or signs of heart problems in the blood.
Estonian: • patsiendid, kellel juba on esinenud Q-sakita müokardiinfarkt (südameinfarkti liik), kui rinnavalu on täheldatud viimase 24 tunni jooksul ja esinevad EKG muutused või on veres täheldatud südameprobleemidele viitavaid muutusi.
English: What is Eptifibatide Accord and what is it used for?
Estonian: Mis on Eptifibatide Accord ja milleks seda kasutatakse?
English: This is a summary of the European public assessment report (EPAR) for Eptifibatide Accord.
Estonian: See on ravimi Eptifibatide Accord Euroopa avaliku hindamisaruande kokkuvõte.
English: If the patient undergoes a percutaneous coronary intervention (PCI or angioplasty, a surgical procedure that is used to unblock narrowed coronary arteries), infusion of Eptifibatide Accord can be continued for up to 24 hours after the procedure, with a maximum treatment duration of 96 hours.
Estonian: Patsientidel, kellele tehakse perkutaanne koronaarne sekkumine (PCI või angioplastikakirurgiline protseduur,millega laiendatakse ahenenud pärgartereid), võib ravi jätkata kuni 24 tundi pärast operatsiooni.
English: Other information about Eptifibatide Accord
Estonian: Muu teave Eptifibatide Accordi kohta
English: For more information about treatment with Eptifibatide Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Eptifibatide Accordiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The patients most likely to benefit from a treatment with Eptifibatide Accord are those at high risk of heart attack in the three to four days after the start of acute (sudden) angina.
Estonian: Kõige tõenäolisemalt saavad Eptifibatide Accordist kasu need patsiendid, kellel on müokardiinfarkti suur oht esimese 3-4 päeva kestel pärast ägeda stenokardia algust, sealhulgas ka need patsiendid, kes läbivad perkutaanse transluminaalse koronaarangioplastika (PTCA, ahenenud südamearterite laiendamise operatsioon).
English: This means that it helps to prevent cells in the blood called platelets sticking together (aggregating).
Estonian: See tähendab, et ravim aitab ennetada teatud vererakkude - trombotsüütide (vereliistakute) - agregatsiooni (kokkukleepumist).
English: Eptifibatide Accord is an inhibitor of platelet aggregation.
Estonian: Eptifibatide Accord on trombotsüütide agregatsiooni inhibiitor.
English: It is not intended to provide practical advice on how to use Eptifibatide Accord.
Estonian: Hindamisaruandes ei anta Eptifibatide Accordi kasutamise praktilisi nõuandeid.
English: Why is Eptifibatide Accord approved?
Estonian: Miks Eptifibatide Accord heaks kiideti?
English: Eptifibatide Accord is a ‘generic medicine'.
Estonian: Eptifibatide Accord on geneeriline ravim.
English: It is available as solutions for infusion (drip) and injection into a vein.
Estonian: Seda turustatakse veeni manustatava infusiooni- ja süstelahusena.
English: Eptifibatide Accord must not be used in patients with severe kidney problems.
Estonian: Raske neeruhaigusega patsientidel ei tohi Eptifibatide Accordi kasutada.
English: Eptifibatide Accord should be given by a doctor who has experience in the management of heart attacks and angina and can only be obtained with a prescription.
Estonian: Eptifibatide Accordi tohib manustada arst, kellel on kogemusi südameinfarktide ja stenokardia ravis.
English: How does Eptifibatide Accord work?
Estonian: Kuidas Eptifibatide Accord toimib?
English: How has Eptifibatide Accord been studied?
Estonian: Kuidas Eptifibatide Accordi uuriti?
English: How is Eptifibatide Accord used?
Estonian: Kuidas Eptifibatide Accordi kasutatakse?
English: What are the benefits and risks of Eptifibatide Accord?
Estonian: Milles seisneb Eptifibatide Accordi kasulikkus ja mis riskid ravimiga kaasnevad?
English: ATC vet code: QJ01MA94
Estonian: ATC-vet kood: QJ01MA94
English: In general the pruritis disappears within a few minutes and the local swelling within a few days.
Estonian: Üldiselt kaob sügelus paari minuti jooksul ning turse paari päevaga.
English: Each tablet contains:
Estonian: Üks tablett sisaldab:
English: Camprodón, s/n°, Finca La Riba, Vall de Bianya, 17813 Girona Spain
Estonian: Camprodón, s/n°, Finca La Riba, Vall de Bianya, 17813 Girona Hispaania
English: These adverse reactions were self-limiting within one or two days and did not require additional treatment.
Estonian: Need tunnused kadusid ühe-kahe päevaga ega vajanud täiendavat ravi.
English: After subcutaneous administration the bioavailability is 96%.
Estonian: Nahaalusi manustamise järgselt on biosaadavus 96%.
English: The volume of distribution is 2.6 l/kg.
Estonian: Jaotumise maht on 2,6 l/kg.
English: Ethanol 8
Estonian: Etanool 8
English: D. STATEMENT OF THE MRLs which are accepted in accordance with Council Regulation (EEC) No 2377/90 and in accordance with Article 31 (3b) of Council Regulation (EEC) No 2309/93 of 22 July 1993, as amended.
Estonian: Mida aktsepteeritakse/võib aktsepteerida vastavalt nõukogu määrusele (EMÜ) nr 2377/90 ja nõukogu 22. juuli 1993. aasta määruse (EMÜ) artikli 31 lõikele 3b ja selle muudatustele.
English: Cardboard boxes of 1, 2 or 10 blisters.
Estonian: Pappkarbid, milles on 1, 2 või 10 blistrit.
English: Dicural coated tablets should be given once a day for at least 5 days.
Estonian: Dicural kaetud tablette tuleb anda üks kord päevas vähemalt 5 päeva.
English: total water consumption of the house at the previous day (litres)
Estonian: eelmisel päeval tarbitud vee hulk (liitrites)
English: A half-life time of 5.8 hours has been observed.
Estonian: Poolestusaeg on 5,8 tundi.
English: After subcutaneous administration the bioavailability is 88% and the volume of distribution is 2.5 l/kg.
Estonian: Nahaalusi manustamise järgselt on biosaadavus 88% ja jaotumise maht 2,5 l/kg.
English: The elimination half-life averaged 9.3 hours.
Estonian: Poolestusaeg oli keskmiselt 9,3 tundi.
English: [Not required on the immediate label] Dispose of waste material in accordance with local requirements.
Estonian: [Not required on the immediate label] Jäätmematerjal hävitada vastavalt kohalikule seadusandlusele.
English: If there is insufficient improvement after 3 days, the treatment can be continued for another 2 days.
Estonian: Kui paranemist ei toimu 3 päevaga, võib ravi jätkata veel 2 päeva.